Brand-name drug makers lose patent thicket weapon against generics

What it does

This bill limits pharmaceutical and biological product makers from suing generic drug applicants and biosimilar makers using multiple patents from the same patent family in a single lawsuit. Under current law, a brand-name drug company can assert many related patents against a generic competitor in one action; this bill caps that at one patent per 'Patent Group' (patents linked by double-patenting disclaimers). The restriction applies only to suits against generic/biosimilar applicants and manufacturers, effective immediately for new applications.

Why we flagged it

The bill's operative mechanism is a procedural limit on patent assertion in a specific litigation context (generic/biosimilar defense). It does not eliminate patents or invalidate them; it restricts the number of related patents a brand-name holder can assert in a single action against generic competitors. This is a targeted litigation reform, not a broad patent policy change.

What the text implies

• The definition of 'Patent Group' relies entirely on double-patenting disclaimers filed at the USPTO. Patent holders who have not filed such disclaimers may not be constrained by this rule, creating a potential loophole for companies that structure their patent portfolios differently.
• The one-patent-per-action limit does not prevent sequential suits against the same generic competitor using different patents from the same group—only the assertion of multiple patents in a single action. A brand-name holder could theoretically file separate actions, though this may trigger counterclaims or estoppel doctrines not addressed in the bill.
• The restriction applies only to suits against generic applicants and biosimilar licensees, not to suits against other competitors (e.g., over-the-counter manufacturers, foreign competitors, or non-pharmaceutical entities). Brand-name holders retain full patent assertion rights in other contexts.
• Applicability is prospective only (applications submitted after enactment). Pending litigation and applications filed before enactment are unaffected, limiting the immediate impact on existing patent disputes.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Generic and biosimilar drugs are the primary mechanism by which ordinary people access affordable medications after patent expiration. By restricting brand-name companies' ability to weaponize patent thickets against generic competitors, this bill reduces litigation costs that would otherwise be passed to consumers and accelerates market entry of lower-cost alternatives. The restriction is narrowly tailored to the generic/biosimilar context and does not eliminate patent rights—only the ability t

Who stands to gain

• generic pharmaceutical manufacturers
• biosimilar manufacturers
• pharmacy benefit managers (via lower drug costs)
• consumers (via lower medication prices)

Named in the bill

35 U.S.C. § 271(e), Federal Food, Drug, and Cosmetic Act § 505, Public Health Service Act § 351(k), 35 U.S.C. § 253 (double-patenting disclaimer), USPTO, generic drug manufacturers, biosimilar manufacturers, brand-name pharmaceutical companies

Where it stands

2 cosponsors: 1 Democrats, 1 Republicans.

• Jul 15, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Jul 15, 2025 — Referred to Senate Committee on the Judiciary · Congress.gov: “Read twice and referred to the Committee on the Judiciary”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

21 lobbying clients named this bill on 28 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $47,282,577 in lobbying spend. A filing names 24 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 97% of bills with at least one filing.

Peter Welch, the sponsor, reported $39,000 in PAC receipts in the 2026 cycle.

• Chamber of Commerce of the U.S.A. — $16,950,000 on 1 filing
• Pharmaceutical Research and Manufacturers of America — $15,770,000 on 2 filings
• Amgen Inc — $2,440,000 on 1 filing
• Biotechnology Innovation Organization — $2,360,000 on 1 filing
• Bayer Corporation (consolidated Report) — $1,820,000 on 1 filing

Lobbying Disclosure Act filings through Jul 22, 2026. A filing shows who paid to lobby on a bill it names, not what changed.